In halothane-nitrous oxide-anesthetized pigs, the effect of the competitive adenosine antagonist, BW-A1433U (a derivative of 1,3-dipropyl-8-phenylxanthine), on postdefibrillation bradyarrhythmia and hemodynamic depression was investigated. In protocol 1, repetitive episodes of ventricular fibrillation lasting 15 seconds before transthoracic DC shock were performed in five animals, before (control) and after the administration of BW-A1433U (5 mg/kg i.v.). An unsuccessful initial shock was immediately followed by a rescue shock of 40 A. In ventricular fibrillation episodes requiring rescue shocks, nine of 19 episodes (47%) exhibited secondor third-degree atrioventricular block at 15 seconds postdefibrillation compared with only one of 16 BW-A1433U episodes (6%). In protocol 2, the efrect of BW-A1433U was determined in the presence of dipyridamole, a nucleoside uptake blocker known to potentiate the cardiac actions of adenosine. To counter the hypotensive effect of dipyridamole, methoxamine was continuously infused at 0.015 mg/kg/min i.v. Sequential episodes of ventricular fibrillation lasting 45 seconds were terminated by shocks of 40 A in the presence of methoxamine alone, after dipyridamole (1.5-7.5 mg i.v.), and after BW-A1433U (5 mg/kg i.v.). Over the first 15 seconds postdefibrillation, BW-A1433U significantly (p<0.05) increased the number of spontaneous beats (31±2) and systolic/diastolic blood pressure (111±4/67±5 mm Hg; mean+SEM; n=9) compared with both methoxamine (16±2 beats; 98±14/52+12 mm Hg; n=5) and dipynrdamole (8±3 beats; 58±11/27±6 mm Hg; n=9), respectively. Rapid infusion of BW-A1433U during dipyridamole postdefibrillation periods raised heart rate and blood pressure to preventricular fibrillation levels within 30 seconds. Thus, BW-A1433U can reverse and prevent postdefibrillation bradyarrhythmia and hemodynamic depression. Endogenous adenosine may be an important mediator of postdefibrillation cardiovascular collapse. (Circulation 1989;80:128-137) B radyarrhythmia and hypotension after ventricular defibrillation usually lead to a fatal outcome that is secondary to prolonged periods of inadequate tissue oxygenation and perfusion.1-3 Adenosine, an endogenous metabolite released during hypoxia and ischemia, exerts multiple depressant actions on cardiovascular function by activation of specific cell-surface receptors.4-10 Due to either cyclic AMP (cAMP)-independent (direct) or cAMP-dependent (indirect, antiadrenergic) actions, adenosine has been shown to relax vascular smooth muscle, reduce atrial and ventric-
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Supported by a Burroughs-Wellcome Research Award. R.C.W.
is a recipient of a NHLBI Physician-Scientist Award (HL-01408). ular contractility, depress pacemaker automaticity, and impair atrioventricular (AV) nodal conduction.4-10 In rodent hearts, adenosine potentiates ventricular overdrive suppression. 11, 12 Moreover, the effect of hypoxia on overdrive suppression appears to be largely secondary to the release of endogenous adenosine.1' Based on the above, it is conceivable that endogenous adenosine released as a consequence of hypoxia and hypoperfusion may contribute to the genesis and maintenance of the bradycardic-hemodynamic collapse associated with cardiopulmonary resuscitation.
Recently, it has been suggested that endogenous adenosine may oppose the actions of catecholamines in a rat model of hemorrhagic shock.13 Moreover, in a similar model, de Garavilla et al14 have reported that several alkylxanthines (i.e., adenosine antagonists) can reverse hemorrhagic shockinduced contractile dysfunction and bradycardia. In pentobarbital-anesthetized dogs, rapid infusion of a selective competitive adenosine antagonist, 8-p-sulfonyl phenyltheophylline (8-PST), reversed the electrophysiologic (i.e., sinus node arrest and highgrade AV nodal block) but not the hemodynamic depression associated with the conversion of prolonged (.2 minutes), ventricular fibrillation (Wesley and Belardinelli, unpublished observations).
In the present study, we sought to determine whether the potent and specific adenosine antagonist, BW-A1433U, a derivative of 1,3-dipropyl-8-phenylxanthine,15 could reverse postdefibrillation bradycardic-hemodynamic collapse under basal conditions and in the presence of dipyridamole, a nucleoside uptake blocker, known to potentiate the cardiac action of adenosine.16
Methods
This study conformed to experimental guidelines based on the principles of the American Physiological Society.
Domestic pigs (Yorkshire) of either sex weighing 45-55 lb. were intubated after mask induction with 3% halothane and supplemental intravenous surital and subsequently maintained on an inhaled anesthetic regimen of 0.3-0.6% halothane and a 1:1 mixture of oxygen and nitrous oxide. This anesthetic regimen has previously been used in the testing of defibrillation threshold in a porcine model. 17 The lowest dose of halothane that maintained the mean aortic pressure greater than 90 mm Hg in the absence of corneal reflexes was used. Ventilation via a Harvard respirator (model 944, Harvard Apparatus, South Natick, Massachusetts) was adjusted to maintain arterial pH and Pco2 between 7.35 and 7.45 and 35 and 45 mm Hg, respectively. Fluid-filled angiographic catheters were advanced into the right femoral artery and right internal jugular veins for measurement of descending aortic and right atrial pressures, respectively. Electrocardiographic lead II and vascular pressures (Statham P23Db transducer, Statham Instruments, Inc, Oxnard, California) were continuously recorded on an electrostatic recorder (model 7758A, Hewlett-Packard, McMinnville, Oregon). A thermodilution Swan-Ganz catheter was advanced through the right femoral vein into the inferior vena cava for drug infusion and continuous measurement of central core temperature. Self-adherent cutaneous electrodes (model 410, R2 Corporation, Morton Grove, Illinois) were firmly attached over the shaven right and left lateral thoracic walls at the transverse level of the heart and secured with an Ace bandage.
Ventricular fibrillation was induced by applying alternating current through a percutaneous quadripolar catheter (6F, United States Catheter and Instrument Corp, Billerica, Massachusetts) positioned in the right ventricle. The endotracheal tube was automatically clamped at peak-inspiration via a solenoid-switch at the induction of ventricular fibrillation. Damped-sinusoidal DC shocks were delivered by a defibrillator (model 43100A, Hewlett-Packard) calibrated to deliver 3,000 V at 400 J across a 50-Q load, which was modified for current delivery through a constant-load current divider circuit as described by Lerman et al. 18 A rhythm strip of 15-second duration was automatically produced with each defibrillation attempt. Voltage delivered across the thorax was measured with a 1,000: 1 voltage divider in parallel with the defibrillator output, and the delivered current was measured with a 0.10 -Q resistor in series with the defibrillator output. Voltage and current waveforms were displayed on a triggered-sweep storage oscilloscope (model 5113, Tektronix, Beaverton, Oregon) with a frequency response from 0.01 to 1 MHz. Before defibrillation trials, transthoracic impedance was calculated from delivered energy and current after a synchronized DC shock at approximately 20 A during sinus rhythm. During each protocol, the variable resistors were adjusted to deliver the desired current and simultaneously maintain a constant 50-fl load to the defibrillator. Thus, a slightly overdamped pulse was delivered (that was within 2% of the selected current) during each defibrillation trial, regardless of the transthoracic impedance.
Chemicals. Dipyridamole was purchased from Boehringer Ingelheim and methoxamine from Burroughs-Wellcome Co. BW-A1433U, a pphenylcarboxyl-substituted derivative of 1,3dipropyl-8-phenyIxanthine (kindly provided by Dr. S. Daluge of Burroughs-Wellcome Co, Research Triangle, North Carolina), is a highly potent and specific competitive adenosine receptor antagonist.15 BW-A1433U was dissolved in an alkalinized saline solution (pH 11.0) at concentration of 2 mg/ml. Experimental Protocols Protocol 1. The objective of this protocol was to determine the effect of BW-A1433U on postdefibrillation rhythm disturbances. Animals in protocol 1 were subjected to repetitive trials of induced ventricular fibrillation lasting 15 seconds before defibrillation. Trials were separated by 7.5 -minute recovery periods. The temperature was maintained below 35.5°C (range, 33.5-35.5°C) because of the protective effect of mild hypothermia on ventricular function.20 Temperature varied by no more than 10 C in a given animal.
On the first ventricular fibrillation trial, each animal received an initial DC shock of 36 A, which invariably defibrillated. On successive ventricular fibrillation trials, the current values of each initial DC shock were stepwise reduced by 2-A decrements. On failure of an initial shock, ventilation and manual sternal compression at 80/min were initiated, followed by an invariably successful rescue shock of 40 A that was delivered at 26-30 seconds of total ventricular fibrillation duration. A trial characterized by the success of the initial shock was termed a first shock conversion (FSC) while one requiring a rescue shock was termed a second shock conversion (SSC).
After the first use of a rescue shock, the stability of current-based defibrillation requirements was established by using an interactive method of currentdose adjustment. On the next and all subsequent ventricular fibrillation trials preceded by SSCs, the current value of the initial DC shock was increased by 1 A. Conversely, if a. preceding ventricular fibrillation trial was characterized by a FSC, the current value of the initial DC shock on the subsequent trial was reduced by 1 A. Testing continued in this manner until at least three FSCs were immediately followed by trials requiring rescue shocks (i.e., SSCs).
Basal defibrillation threshold was determined by averaging the current values of the FSCs. Animals then received either BW-A1433U (group A: 5 mg/ kg i.v.; n=5) or an alkalinized saline placebo of equivalent volume (group B: n=5). Subsequent postintervention trials were conducted via the interactive method previously described and postintervention defibrillation threshold was determined in an analogous manner.
To quantitate postdefibrillation electrophysiologic depression, we analyzed the occurrence of AV nodal block at 15 seconds postdefibrillation and the sinus cycle length and P-R interval at the tenth sinus beat (which was analyzed to avoid effects of immediate postshock ventricular or atrial ectopy on sinus node automaticity or AV nodal conduction).
Protocol 2A. The objective of this protocol was to determine whether BW-A1433U could reverse or prevent postdefibrillation bradyarrhythmia and hemodynamic depression noted in the presence of dipyridamole, an adenosine-uptake blocker. Temperature ranged from 36°to 370 C. To counter the hypotensive effect of dipyridamole, methoxamine at 0.015 mg/kg/min i.v. was continuously infused. After 15 minutes of methoxamine administration, intravenous dipyridamole (total, 1.5-7.5 mg) was given as sequential boluses (0.5 mg) at 30-60second intervals until blood pressure returned to premethoxamine levels. Ventricular fibrillation of 45 seconds duration was induced followed by a DC shock of 40 A. Postshock sequelae (i.e., rhythm disturbances and hemodynamic depression) were observed without intervention for 30 seconds. When systolic pressure equaled or exceeded 40 mm Hg, a rapid intravenous bolus of BW-A1433U (5 mg/kg) was injected and the response noted. When systolic pressure was less than 40 mm Hg, BW-A1433U was infused followed by no more than 30 seconds of chest compression, which was performed to promote drug delivery. In a subset of animals, an equivalent volume of BW-A1433U diluent (placebo) was injected before BW-A1433U administration. After recovery (7.5 minutes), additional intravenous dipyridamole (2-3 mg) was administered in divided doses to demonstrate continued antagonism of dipyridamole's hypotensive effect of BW-A1433U. In the presence of dipyridamole and BW-A1433U, a second ventricular fibrillation episode of 45 seconds duration was then repeated, followed by a DC shock of 40 A.
Protocol 2B. The procedure for protocol 2B was essentially the same as the one outlined in protocol 2A except that the initial fibrillation-defibrillation sequence (45 seconds of ventricular fibrillation followed by DC shock at 40 A) was performed after 15 minutes of methoxamine administration. This sequence was followed by a 7.5-minute recovery period before intravenous dipyridamole loading and continuation of the steps outlined in protocol 2A.
STATISTICAL ANALYSIS. Statistical analysis of variables was based on Student's t distribution for paired and unpaired data.19 p values less than 0.05 indicated statistically significant differences. All values are expressed as the mean±SEM.
Results
BW-A1433U: Preliminary Data
Prior observations had revealed that BW-A1433U in the doses used in this study (5 mg/kg i.v.) had no significant basal effects on blood pressure and heart rate. The sinus cycle lengths before and after BW-A1433U were 438+20 and 424±17 msec, respectively (n=6, p>0.05). The blood pressures before and after BW-A1433U were 114±7/83±8 and 117±8/ 87±9 mm Hg, respectively (n=6).
Intravenous bolus injections of adenosine in the absence of BW-A1433U markedly lowered blood pressure in a dose-dependent manner. The aortic and systolic blood pressures were 119±16/87+15 mm Hg for control (n= 15), 95±18/70± 18 mm Hg for adenosine 50 jig/kg (n=15), and 82±14/52±10 mm Hg for adenosine 200 ,g/kg (n=8). Intravenous bolus injections of adenosine had a small but insignificant effect on sinus cycle length, presumably secondary to a reflex increase in sympathetic drive accompanying the fall in aortic systolic and diastolic blood pressure. For example, preadenosine sinus cycle length equaled 388±22 msec compared with 402±19 msec after the administration of adenosine 200 ,ug/kg (n=5). Note the effect of adenosine on sinus cycle length could not be clearly defined in all animals due to the presence of episodic atrial dysrhythmia.
After pretreatment with BW-A1433U (5 mg/kg i.v.), bolus injections of adenosine were without effect (i.e., BW-A1433U completely [100%] antagonized the effect of 200 jug/kg adenosine on blood pressure). By contrast, the same dose of 8-PST antagonized the effect of adenosine by 87%. 8-PST also had demonstrated no effect on sinus cycle length and blood pressure under basal conditions (i.e., in the absence of adenosine). ing the control period (group A, n=5). Similarly, defibrillation threshold values for placebo and control were 29.2±1.9 and 30.9+1.4 A, respectively (group B, n=5).
In contrast, BW-A1433U substantially prevented postdefibrillation depression of sinus node automaticity and AV nodal conduction. With regard to FSCs, BW-A1433U significantly reduced the P-R interval and sinus cycle length compared with control when intervals at the tenth beat after successful defibrillation were analyzed (Figure 1 and Table 1 ).
The effect of BW-A1433U on reversing AV nodal conduction disturbances was more pronounced when a rescue DC shock was required (i.e., for SSCs; Figures 1 and 2) . In 47% (nine of 19) of control SSC episodes, less than 10 beats could be counted during the first 15 seconds postdefibrillation. Of these nine episodes, seven exhibited high-grade (>2:1) AV block and the remaining two displayed complete AV block without ventricular capture throughout the first 15 seconds postdefibrillation (Figure 2 ). By contrast, in the presence of BW-A1433U, no SSC episode exhibited less than 10 beats during the first 15 seconds after defibrillation, and in only one of 16 episodes was a rhythm other than sinus (i.e., 2:1 AV block) noted at the tenth beat. After SSCs, BW-A1433U significantly increased the number of beats observed in the first 15 seconds after defibrillation (33.2+1.9 vs. 14.2±3.2 beats before BW-A1433U;p <0.02; n=5). In addition, after SSCs, the mean cycle length of the first three beats postdefibrillation was significantly shorter after BW-A1433U (i.e., 930±22 vs. 2,638±386 msec before BW-A1433U;p<0.05; n=5). Protocol 2 Methoxamine infusion significantly increased sinus cycle length and aortic pressures before the administration of dipyridamole (Table 2) . Dipyridamole (1.5-7.5 mg i.v.) lowered blood pressure to premethoxamine levels (i.e., baseline) while further lengthening sinus cycle length ( Table 2 ). Compared Recordings are electrocardiographic lead II registered at a sweep speed of 25 mm/sec. Records were obtained after rescue shocks (i.e., second shock conversions) before (Panel A, control) and after the intravenous administration of BW-A1433U at 5 mg/kg (Panel B, BW-A1433). In Panel A, no ventricular depolarization occurs during the 15 seconds after defibrillation. At the tenth sinus p wave, the sinus cycle length is 520 msec. In Panel B, BW-A1433Uprevents the occurrence ofatrioventricular block. At the tenth beat after defibrillation, the sinus cycle length and P-R intervals are 400 and 120 msec, respectively. Recordings in Figures 1 and 2 were obtained from different animals.
with methoxamine alone, dipyridamole markedly reduced postdefibrillation aortic pressure and the number of spontaneous beats recorded over the initial 15 seconds postdefibrillation (Table 3) . By contrast, after pretreatment with BW-A1433U, postdefibrillation aortic pressure and the number of spontaneous beats were significantly more than in the presence of methoxamine alone and after dipyridamole loading (Table 3 ). After defibrillation in the presence of dipyridamole, rapid infusions of BW-A1433U significantly increased postdefibrillation heart rate and aortic systolic/diastolic pressure from 48±12 to 110+6 beats/min and from 69+12/ 36±7 to 113±7/78±10 mm Hg, respectively, within 30 seconds of administration (Figures 3 and 4 ). In four of nine experiments, inadequate pulse pressure (i.e., systolic pressure <40 mm Hg) required the use of manual chest compression to facilitate drug delivery ( Figure 3 ). However, in five other instances, when pulse pressure was adequate for drug delivery (i.e., systolic pressure >40 mm Hg), BW-A1433U also reversed hemodynamic collapse. In one instance, this occurred after a further deterioration in blood pressure (Figure 4 ). In two cases tested, an equivalent volume of placebo (i.e., BW-A1433U diluent) given before BW-A1433U had no effect on postdefibrillation heart rate or blood pressure. In these two animals, after placebo injection, average heart rate fell by 6 beats/min and mean aortic pressure increased by 3 mm Hg. Before the final episode of ventricular fibrillation, in the presence of BW-A1433U during sinus rhythm, intravenous dipyridamole (2-3 mg) had no effect on heart rate or blood pressure.
Discussion
The findings of the present study suggest that endogenously released adenosine significantly mediates postdefibrillation sinus slowing, AV conduction disturbances, and hypotension in an anesthetized porcine model. The potent, competitive, and rhythm is noted after defibrillation. Panel B: BW-A1433 after defibrillation. BW-A1433U was injected before the beginning of the left-hand panel at 30 seconds postdefibrillation. Chest compression is initiated at the dot. Right-hand panel denotes reversal of electrophysiologic and hemodynamic depression at 1 minute after defibrillation (sinus cycle length, 520 msec; aortic pressure, 125/90 mm Hg). Panel C: Defibrillation after BW-A1433. Four seconds of complete atrioventricular block is followed by sinus rhythm (sinus cycle length, 440 msec) and hemodynamic recovery (aortic pressure, 110/65 mm Hg). Ventricular bigeminy and nonsustained ventricular tachycardia are noted at the end of the tracings. specific adenosine antagonist, BW-A143U,15 COMpletely reversed the effect of defibrillation on AV nodal conduction (i.e., P-R interval prolongation or AV block). The reversal of AV nodal conduction disturbances by BW-A1433U was accompanied by a concomitant reduction in sinus cycle length. Thus, the extent to which BW-A1433U attenuates postdefibrillation AV nodal conduction delay is underestimated because an increase in sinus rate would be expected to prolong AV nodal conduction.21 This finding is consistent with previous observations in guinea pig hearts suggesting that the AV node is the most sensitive of myocardial tissues to the electrophysiologic actions of adenosine22
In the presence of the nucleoside uptake blocker, dipyridamole, which is known to elevate plasma levels of the nucleoside'6 and to potentiate the cardiovascular actions of adenosine, BW-A1433U reversed postdefibrillation electrophysiologic depression and hemodynamic collapse. Moreover, such reversal was not noted after placebo administration indicating that hemodynamic and electrophysiologic improvement was not merely time dependent or secondary to chest compression when performed in the setting of severe hypotension. Thus, the data support that BW-A1433U, under the experimental conditions, was adequately delivered to myocardial and peripheral sites of action. The mechanism of action of BW-A1433U is most consistent with adenosine antagonism and not phosphodiesterase inhibition or the release of catecholamines, alternative actions ascribed to alkylxanthines.33 Secondary to low lipid solubility, BW-A1433U does not easily penetrate cell membranes and, thus, is unlikely to inhibit intracellular phosphodiesterase. 15 In isolated guinea pig hearts, BW-A1433U was found to be 100-fold more potent as an adenosine antagonist than phosphodiesterase inhibitor.15 Moreover, when present, the ability of alkylxanthines to inhibit phosphodiesterase bears no relation with their potency to antagonize the effects of adenosine.10 The efficacy of alkylxanthines in reversing the effects of adenosine are not altered by f3-adrenergic blockade or reserpinization. 16 Thus, based on the above, it is unlikely that phosphodiesterase inhibition or the release of endogenous catecholamines can account for or explain the "antiadenosine" action of alkylxanthines.
Although the effect of BW-A1433U on phosphodiesterase inhibition and endogenous catecholamine release was not directly tested in the present porcine model, the data support adenosine antagonism as the mechanism of action. BW-A1433U completely antagonized the effect of exogenously administered adenosine and of dipyridamole, both before ventricular fibrillation and after defibrillation. BW-A1433U had no basal effect on heart rate or blood pressure. Endogenous catecholamine release or phosphodiesterase inhibition would be expected to increase heart rate and alter basal hemodynamics. 34, 35 Experiments using nucleoside uptake blockade were performed in the presence of methoxamine. Significant sinus slowing was noted after the infusion of methoxamine, possibly secondary to enhanced vagal tone or a direct, negative chronotropic effect.23 It is unlikely, however, that methoxamine-induced slowing contributed much to postdefibrillation electrophysiologic depression because BW-A1433U markedly reversed both postdefibrillation sinus bradycardia and AV nodal block.
Moreover, before the first episode of ventricular fibrillation in protocol 2, additional sinus slowing occurred after dipyridamole administration, a finding most likely secondary to an increase in interstitial levels of adenosine.
Of interest was the lack of an effect of BW-A1433U (i.e., adenosine antagonism) on the current requirements for defibrillation. In an energy-based conscious dog model, Ruffy et a124 had reported a lowering of energy requirements for defibrillation after infusion of the nonspecific adenosine antagonist, aminophylline, suggesting that adenosine antagonism may facilitate defibrillation. Despite the fact that current is a superior predictor of defibrillation compared with energy,18 BW-A1433U did not lower current-based defibrillation threshold in our model. However, an effect of adenosine antagonism on defibrillation may not be present with short ventricular fibrillation duration as endogenous adenosine release may be insufficient.
Substantial evidence exists to suggest that the excessive production of endogenous adenosine may play a deleterious role during cardiopulmonary resuscitation. The release of endogenous adenosine is markedly enhanced during hypoxia and ischemia.4-6 The negative chronotropic and dromotropic effect of adenosine, coupled with its enhancement of overdrive suppression, could contribute to severe bradycardia and asystole.7-12 In addition, adenosine relaxes vascular smooth muscle and, thus, might contribute to postdefibrillation hypotension (i.e., hemodynamic collapse9). Furthermore, by attenuating the activity of previously stimulated adenylate cyclase, endogenous adenosine might also counter the positive inotropic and vasotonic effects of catecholamines, either administered exogenously or endogenously released by hypoxia, hypotension, and electrical shock. [25] [26] [27] Additional observations also suggest that endogenous adenosine may be released secondary to DC countershock alone. In normoxic, isolated, perfused guinea pig hearts, directly applied DC shock was found to significantly increase effluent levels of Note that the aortic pressure had fallen to 60/25 mm Hg. After injection of BW-A1433U, in the absence of chest compression, the aortic pressure rises to 125/95 mm Hg and the sinus cycle length equals 410 msec as noted in the right-hand panel (1 minute after defibrillation). Panel C: Defibrillation after BW-A1433. Transient 3:1 atrioventricular block is followed by sinus rhythm (sinus cycle length, 400 msec) and an aortic pressure of 125/90 mm Hg. adenosine in an energy dose-dependent manner (Wesley and Belardinelli, unpublished observations). In 1931, Bennett and Drury28 noted the release of adenosine with thermal injury to isolated perfused hearts, suggesting that such release might be a nonspecific response to cell injury. A recent study has provided additional insight into the mechanism by which endogenous adenosine may be released with countershock. In normoxic dogs during sinus rhythm, Gaba et a129 have reported that closely coupled internal DC shocks in the absence of myocardial hypoperfusion can cause transient net lactate production. The authors hypothesized that repetitive DC shocks cause mitochondrial dysfunction, leading to anaerobic metabolism. The hydrolysis of ATP under such circumstances should lead to enhanced adenosine production and release.
Several findings in our study amplify this contention. AV nodal conduction disturbances were markedly worsened by closely coupled second shocks such as in protocol 1. Moreover, the effect of a second shock on AV nodal conduction was completely reversed by the adenosine antagonist, BW-A1433U. With regard to clinical relevance, Weaver et a130 observed a high incidence of postdefibrillation AV block in patients subjected to successive high energy shocks.
Hemodynamic collapse after nucleoside uptake blockade persisted in the presence of vasoconstricting doses of methoxamine, an a-adrenergic agonist. Thus, ar-adrenergic-mediated vasoconstriction (i.e., methoxamine) may be insufficient to overcome the vasodilatory action of excessive endogenous adenosine. Levels of extracellular endogenous adeno- l.w sine achievable with short-term arrest (45 seconds) in the presence of nucleoside uptake blockage may be comparable to levels noted during prolonged arrest and resuscitation. Thus, although speculative, endogenously released adenosine could account for, in part, the lack of response to a-adrenergic agonists observed during prolonged resuscitation.31,32 Moreover, the results of this study also suggest unsuspected dangers if cardiac arrest should occur during therapy or diagnostic procedures using nucleoside uptake blockers, such as intravenous dipyridamole radionuclide scintigraphy. In summary, the potent and specific adenosine antagonist, BW-A1433U, reversed and prevented postdefibrillation sinus node suppression, AV nodal block, and dipyridamole-enhanced peripheral vasodilation. These findings support the hypothesis that endogenously released adenosine may be a significant mediator of the genesis and maintenance of electrophysiologic and hemodynamic depression after defibrillation. In addition, endogenous adenosine might alter myocardial function by inducing coronary steal or a maldistribution in coronary blood flow during resuscitation.36 This hypothesis is best tested during the performance of cardiopulmonary resuscitation using techniques that can characterize and quantitate total and regional myocardial blood flow. In conclusion, an important new perspective based on the role of endogenous adenosine is offered with regard to the pathophysiology of cardiac resuscitation.
